ReviewCureus2025
A Descriptive Summary of Tumor-Associated MUC1 (TA-MUC1) Expression in Epithelial Malignancies: A Systematic Review of Case Reports and Case Series.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-associated MUC1 (TA-MUC1) is a hypoglycosylated variant of MUC1 that is aberrantly expressed in many epithelial malignancies. Its limited presence in normal tissues and immunogenic properties suggest potential as a target for antibody-drug conjugates and cancer immunotherapy. However, the clinicopathological spectrum and therapeutic context of TA-MUC1-positive tumors remain insufficiently characterized. We conducted a systematic review of case reports and case series describing immunohistochemically confirmed TA-MUC1 expression in malignant tumors. A total of 73 individual cases from 61 publications were included. Data extraction covered demographics, tumor features, TA-MUC1 expression, treatments, outcomes, and associated biomarkers. TA-MUC1 expression was identified across a wide range of tumor types, most frequently in gastrointestinal, breast, and gynecologic cancers, but also in less common malignancies such as sarcomatoid carcinoma and pleural mesothelioma. Expression was frequently retained in metastatic sites. Immunohistochemical staining varied in intensity and methodology, with strong expression often associated with recurrence or aggressive clinical behavior. Multimodal therapy was commonly reported. Across cases, progression-free survival (PFS) was available in 56 of 73 (76.7%) cases. Among these, 47 of 56 (83.9%) had a documented progression event, whereas nine of 56 (16.1%) were censored (progression-free at last follow-up). The median PFS was 12.0 months (IQR 6.0-19.5; range 0.0-118.0 months). Overall survival (OS) was available in 56 of 73 (76.7%) cases. Among these, 14 of 56 (25.0%) deaths were reported, and 42 of 56 (75.0%) observations were censored (alive at last follow-up). The median OS was 12.0 months (IQR 8.0-26.0; range 0.5-118.0 months). Co-expression with biomarkers such as programmed death-ligand 1 (PD-L1) and human epidermal growth factor receptor 2 (HER2) was occasionally observed. These findings demonstrate that TA-MUC1 has been documented in diverse malignancies, including rare and metastatic presentations. The descriptive evidence supports its potential relevance as a therapeutic target and highlights the need for standardized evaluation and prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.